Acute Stroke Are We Doing All We Can?

Advocate Lutheran General Hospital Neuroscience Institute presents Acute Stroke Are We Doing All We Can? Saturday, October 26, 2013 8 am– 12 pm Advoc...
Author: Darlene Harper
3 downloads 0 Views 2MB Size
Advocate Lutheran General Hospital Neuroscience Institute presents

Acute Stroke Are We Doing All We Can? Saturday, October 26, 2013 8 am– 12 pm Advocate Lutheran General Hospital Johnson Auditorium advocatehealth.com/luth/neurosciences-institute

Agenda Acute Stroke - Are We Doing All We Can? Saturday, October 26, 2013 Advocate Lutheran General Hospital Johnson Auditorium 7:15 am – 8:00 am

Registration and breakfast

8:00 am – 8:05 am

Welcome and Opening Remarks Jerry Bauer, MD

8:05 am – 8:55 am

Thrombolysis for Acute Ischemic Stroke: Past, Present, & Future K. Michael Welch, MD, ChB, FRCP

8:55 am – 9:45 am

Endovascular Treatment of Acute Stroke: Where We’ve Been and Where We’re Going Scott Geraghty, MD

9:45 am – 10:00 am

Break

10:00 am – 10:50 am

More Than a Pound of Cure: An Update On Recurrent Stroke Prevention Philip Gorelick, MD, MPH

10:50 am – 12:05 pm

Case Presentations and Panel Discussion Case No. I – MCA Embolectomy requiring carotid stent placement Case No. II – Extracranial arterial dissection Case No. III – Management of symptomatic high grade carotid stenosis Moderator: W  ayne Rubinstein, MD Panel: T  homas J. Grobelny, MD Philip Gorelick, MD, MPH, FACP Timothy Mikesell, MD K. Michael Welch, MD, ChB, FRCP

12:05 pm

Closing Remarks Wayne Rubinstein, MD

To view and download the presentations, please visit: advocatehealth.com/strokecare

Course Objectives: 1. Participants should adhere to current TPA practice guidelines, recognizing when to refer and how to counsel patients for emergent care of acute neurological symptoms. 2. Participants should be aware of endovascular technologies in the management of patients with stroke, aneurysm, and extracranial stenosis. 3. Participants should implement current secondary stroke prevention guidelines into patient care. 4. Participants should comprehend and be able to assist patients in making informed decisions regarding acute stroke management. Target Audience: Nurses and physicians including internal medicine, family practice, geriatrics, emergency medicine, neurology, urgent care, vascular surgery, neurosurgery Format: Case discussion, panel discussion and lectures Disclosures: i. C  ourse Planners – Jerry Bauer, MD, Wayne Rubinstein, MD, Jessica Sanford, Susan Okuno-Jones, Mike Busky, Sylvia Regner, and Lynn Klassman do not have any relevant financial relationship. ii. Speakers – Philip Gorelick, MD, has indicated a financial relationship with the following commercial interests: Lundbeck, Inc. (research), Boehringer Ingelheim (speaker), Vindomedical (speaker), Pfizer (speaker), and Bayer (steering committee member). Thomas J. Grobleny has indicated a financial relationship with the following commercial interests: Penumbra (stock). Jerry Bauer, MD, Wayne Rubinstein, MD, Scott Geraghty, MD, K. Michael Welch, MD, and Tim Mikesell, MD, do not have any relevant financial relationships to disclose. Financial Support: This activity is sponsored by Advocate Lutheran General Hospital. Accreditation statement: Advocate Health Care is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Advocate Health Care (OH-368, 10/1/2014) is an approved provider of continuing nursing education by the Ohio Nurses Association (OBN-001-91), an accredited approver by the American Nurses Credentialing Commission on Accreditation. Credit designation statement: Advocate Health Care designates this live activity for maximum of 3.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 3.7 contact hours will be awarded for successful completion of the program by the American Nurses Credentialing Commission on Accreditation. Criteria for successful completion includes attendance of the entire event and completion of an evaluation.

Speakers’ Bios Scott Geraghty, MD Dr. Scott Geraghty grew up in the suburbs of Denver, Colorado and attended the University of Colorado at Boulder for his undergraduate degree where he majored in molecular, cellular and developmental biology. After college, he studied medicine at the University of Colorado School of Medicine in Denver, Colorado. He went on to complete his residency in diagnostic radiology as well as fellowships in diagnostic neuroradiology and endovascular neurosurgery/interventional neuroradiology at the University of Virginia in Charlottesville, Virginia, under Dr. Mary Lee Jensen. Dr. Geraghty joined Advocate Medical Group and Advocate Neurovascular Center in July, 2013. His current practice involves the treatment of all Neuroendovascular conditions including, but not limited to, aneurysm coiling, extra and intracranial stenting, and the acute treatment of stroke. Philip B. Gorelick, MD, MPH, FACP Dr. Philip B. Gorelick is the Medical Director of the Hauenstein Neuroscience Center, Saint Mary’s Health Care, Grand Rapids, Michigan (February 6, 2012-present), Professor, Translational Science and Molecular Medicine, Michigan State University College of Human Medicine, previously was the John S. Garvin Professor and Head, Department of Neurology and Rehabilitation, University of Illinois College of Medicine at Chicago (2003-Jan. 2012) and Jannotta Presidential Professor in the Department of Neurosciences, Rush University. Dr. Gorelick has numerous publications in the areas of stroke prevention and risk factor identification, vascular dementia, and stroke in African Americans. He received continuous funding from the US National Institute of Health (NIH) from1987-2005 and led two important NIH initiatives: The African American Antiplatelet Stroke Prevention Study, a recurrent stroke prevention clinical trial, and Risk Markers for Dementia After Stroke, an advanced imaging study to determine epidemiologic and MRI markers for vascular dementia and vascular cognitive impairment. Dr. Gorelick has served as an advisor to the NINDS/NIH, Center for Medicare and Medicaid Services, and US FDA. He is Editor-in-Chief Emeritus of Neuroepidemiology; a member of the Editorial Board of Stroke; a recipient of the National Stroke Association (NSA) Visionary in Practice Society Award 2000, the William Feinberg Excellence in Clinical Stroke Award 2004, the Golden Apple and AOA Teacher of the Year Awards; past Chair of the NSA Stroke Prevention Advisory Board and a past member of the Board of Directors of the Midwest Affiliate of the American Heart Association; and a recipient of a Good Housekeeping Citation for one of the top US stroke physicians. Also, Dr. Gorelick has been awarded the Gainey Lectureship at Mayo Clinic in 2005 and the Henry Barnett Lectureship in Canada in 2005, and has been the Chair of the International Stroke Conference of the American Heart Association; a member of the American Stroke Association Stroke Advisory Board; and a member of the National Stroke Association Board of Directors.

K. Michael Welch, MB, ChB, FRCP On December 2, 2002, Dr. K. Michael Welch assumed the presidency of Rosalind Franklin University of Medicine and Science. Dr. Welch is a neurologist and world-renowned researcher whose career has focused on the study of brain function and structure in cerebrovascular disease, stroke and migraine. Dr. Welch earned his medical degree at the University of Bristol School of Medicine, United Kingdom and came to the United States in the early 1970s. He held several positions at Baylor College of Medicine (Houston, Texas) including Chief of Neurology at the Ben Taub Hospital before relocating to Michigan in 1981 to become the founding chair of the Department of Neurology at Henry Ford Hospital (HFH), now the Henry Ford Hospital and Health Sciences Center which, as vice president for Academic Affairs, he founded and was instrumental to negotiations that culminated in its academic affiliation with Case Western Reserve University. Also at HFH, Dr. Welch was director of the NMR Research Center, the Principal Investigator of two NIHfunded centers for stroke and headache research, and the clinician responsible for the overall conduct of the NINDS tissue plasminogen study (the first to establish effectiveness of thrombolysis in acute stroke). He also became the Principal Investigator of the SPARCL trial, the first to establish statin treatment for secondary stroke prevention. In 1999 Dr. Welch served as Vice Chancellor for Research at the University of Kansas Medical Center and President, Research Institute. He also established the Hoglund Brain Imaging Center at KU and initiated construction of a new sixty million dollar basic science building funded by the Kansas legislature. Dr. Welch continues to serve NIH as chair of several oversight committees for clinical trials. He has served as Clinical Professor at the University of Michigan, Professor of Neurology at Case Western Reserve University, and as Adjunct Professor at Oakland University and the University of New Mexico. Since becoming President of Rosalind Franklin University in 2002, Dr. Welch renamed the University and successfully implemented a full institutional assessment that launched a new mission and vision for the university, integrating the education of all health professions with the goal of enhanced delivery of health care into a model of inter-professional education. In 2012 Dr. Welch established an Alliance for Health Sciences with DePaul University. In July 2006, Dr. Welch received an honorary Doctorate of Medicine Degree from his alma mater, the University of Bristol.

Thomas J. Grobelny, MD Dr. Thomas J. Grobelny was born in Poland and finished Medical School in Wroclaw, Poland. He came to the United States in 1989 to pursue his postgraduate medical training. His early neurovascular knowledge was shaped by Dr. Benet Stein and Dr. Sadek Hilal at the New York Neurological Institute of Columbia University in New York, where he received neuroradiology training during his residency. He continued his training as a fellow in Endovascular Neurosurgery/ Interventional Neuroradiology under Dr. Robert Rosenwasser at the Thomas Jefferson University Hospital in Philadelphia and under Dr. Fernando Vinuela at the UCLA. Dr. Grobelny is a pioneer of Endovascular Stroke treatment and is leading the way in clinical research to advance interventional stroke and brain aneurysm therapy. His work in a pivotal clinical trial led to the FDA approval of the first stroke thrombectomy device in 2004, called the Merci retrieval device. In 2000 as the Director of Neurointerventional Surgery he co-founded and built one of the busiest stroke centers in the United States, the Mid America Brain and Stroke Institute at the Saint Luke’s Hospital in Kansas City. Dr. Grobelny came to Chicago in 2006 joining the Chicago Institute of Neurosurgery and Neuroresearch (CINN), as the Director of Endovascular Neurosurgery. In 2010 CINN physicians’ practice merged with the NorthShore University Healthcare, creating the Northshore Neurological Institute. In January of 2013 Dr. Grobelny joined Advocate Medical Group as the Senior Medical Director of Endovascular Neurosurgery and founded the Advocate Neurovascular Center at Advocate Health Care. He continues to strive to build the largest and most comprehensive stroke network in the Chicagoland. He is an active lecturer and researcher. His professional pursuit focuses on the advances in endovascular stroke and brain aneurysm treatments through clinical practice and research. Tim Mikesell, MD Dr. Tim Mikesell has been on staff at Advocate Lutheran General Hospital since 2002. He is the Medical Director of Stroke and Division Chief of Neurology. He is also Chairperson for the carotid angioplasty and stenting comittee at Lutheran General Hospital. He attended medical school at Michigan State University College of Osteopathic Medicine graduating in 1995. He completed an Osteopathic Rotating Internship at Sparrow Hospital in Lansing, Michigan and then a Preliminary Medicine Internship at the Cleveland Clinic. He then pursued his Neurology Residency at the Cleveland Clinic graduating in 2000 and in his last academic year served as Chief Resident. Dr. Mikesell has participated in clinical stroke trials for acute stroke treatment and secondary stroke prevention throughout his career and also has interest in headache medicine.

Jerry Bauer, MD Dr. Jerry Bauer is board certified in neurological surgery. He earned his medical degree from the University of Illinois in 1974, as well as his undergraduate degree in Biology from the same institution. He completed a residency in neurological surgery at the University of Illinois. Dr. Bauer has academic appointments at Rush University and the University of Illinois. In addition to currently being a member of the medical staff at Advocate Lutheran General Hospital as an attending in the Division of Neurosurgery, he also assumed the Co-Medical Director role of the Neuroscience Institute at Advocate Lutheran General Hospital in 2012. While holding several committee and board positions within the hospital and community, Dr. Bauer is the President and Managing Director for the Center for Brain and Spine Surgery, Park Ridge, IL. He is an active member of several professional organizations such as the American Association of Neurological Surgeons and American College of Surgeons, and has been recognized by several prestigious honors including National Guide to Top Doctors; Castle Connolly Medical Ltd., Top Neurosurgeon in Chicago; Chicago magazine, Chicago Super Doctors; U.S. News and World Report, Who’s Who in America, and many more. Dr. Bauer resides in the greater Chicago area and is married with three children and seven grandchildren. Wayne Rubinstein, MD Dr. Wayne Rubinstein joined the medical staff at Lutheran General Hospital in 1991, and is the Co-Medical Director of the Advocate Lutheran General Hospital Neuroscience Institute. He currently Chairs the Pharmacy and Therapeutics Committee, and is the Medical Director of the Sleep Disorders Center at Advocate Lutheran General Hospital. Dr. Rubinstein attended the Pritzker School of Medicine at the University of Chicago, where he completed an internship in Internal Medicine followed by residency in Neurology, and fellowship training in Clinical Neurophysiology and Sleep Medicine. His clinical practice interests include multiple sclerosis, myasthenia gravis and immunologic disorders of the nervous system. Dr. Rubinstein is a member of the Myasthenia Gravis Foundation of Illinois Medical Advisory Board, and is an Assistant Clinical Professor of Neurology at the University of Illinois College of Medicine.